MedTrace Logo

D-Cycloserine and Social Skills Training in Autism Spectrum Disorders

NCT01086475 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2016-04-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).

Conditions

  • Autistic Disorder
  • Asperger's Disorder
  • Pervasive Developmental Disorder NOS

Interventions

DRUG

D-cycloserine

50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions

DRUG

Placebo

Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Indiana University

    lead OTHER

Principal Investigators

  • Noha F. Minshawi, Ph.D. · Indiana University School of Medicine

  • Craig A. Erickson, M.D. · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01086475 on ClinicalTrials.gov